Avance Workshops
2013 - October 22/23 - License Contract and Company Valuation - Boston
Avance Newsletter
- Comparables
- Evolution of valuation
- Sensitivities in valuation
- High finance in biotech?
- Phase 2a and 2b transition probabilities
- How to value option agreements?
- Early-stage project valuation myths
- NPV vs. rNPV
- Deal Analysis: CellGenesys - Takeda
- Survey on discount rates in biotech
- Should we discount by project or by company? (continued)
- Should we discount by project or by company?
- Deal Analysis: Adnexus-BMS
- Black's risk-free discounting rule
- Deal Analysis: Ardea-Bayer
- How Biotech Stocks Behave
- Deal Analysis: Plexxikon - Roche
- Why drug prices must be high
- Deal Analysis of Celldex-Pfizer
- Staged Take-Overs: New deal structure on the rise
- Risk Premium
- Deal Analysis of KyowaKirin-Amgen
- Biotech Success Rates: NCEs vs. Biologicals
- Real Options: Dos and Don'ts
- Optimal Portfolio Structure
- Employee Stock Option Plans
- Success Rates in Biotech: Going the Wrong Way
- Early-Stage Licensing: How to Determine Sublicensing Terms
- Avance Survey on Financial Crisis and Impact on Biotech and Pharma Companies
- Funny Valuations
- Why are royalties up-tiered?
- Arbitrary Terminal Value
- P/E Ratio for Biotech Valuation.
- Multi-indication Deals - How to Value Them.
- Co-Development Deals - How to Determine a Fair Share?
- Biotech Taxes - Effects on Valuation?
- Reading Deals - How to Interpret Licensing Deals
- No-Dilutive Financing Alternatives
- Forecasting Sales - Competition Scenarios
- Discount Rates in Pharma and Biotech
- Discovery & Preclinical Deals: What's realistic?
- The US$ 1 bio drug. A fairytale